transfusions. if needed, were with irradiated packed red blood cells. After completion of the renal transplant procedure. 3 x lOH unmodified bone marrow cellslkg, isolated from the donor vertebral bodies. were infused via central line (3). Bone marrow infusion was performed at the time of closure of the transplant incision. or shortly thereafter in the recovery room. In the 2 patients who received islets. isolation was according to previously described techniques (5), The islets were infused into the portal vein. after completion of the kidney transplant. All of the protocols were approved by the Institutional Review Board of the University of Pittsburgh.
Just prior to transplantation. 40 ml of blood was drawn and placed in heparinized tubes. Postoperatively, blood was drawn weekly for the first month. and monthly thereafter. for chimerism studies. which included fluorescent activated cell sorter analysis (FACS), polymerase chain reaction (PCR), and V-chromosome analysis by both competitive PCR (cPCR) and fluorescent in-situ hybridizatIOn 1 FISH) of cytospin samples (in the case of female recipients of kidneys from the male donors!.
The mean follow-up for the 10 kidnev/bone marrow recipients is 9.92:4.7 months: all are alive and well. and all have functioning allografts. The mean serum creatinine and BUN are 1.62:0.4 mg/dl. and 232:8 mg/dl. Five (50%) patients have been weaned off steroids. The two islet recipients remain on insulin: they both have evidence of C-peptide production 10.44 and 0.11 pmoVml). but at levels insufficient to allow for insulin independence. '!\vo (20%) patients experienced early kidney non function and required dialysis during the first postoperative week. The incidence of acute rejection was 50% 15 patients). All rejection episodes were responsive to steroids andlor an increase in the FK 506 dosage. No patient required antilymphocyte therapy. Cytomegalovirus ICMV) was seen in 2 (20'7c) patients and was treated successfully with intravenous gancyclovir. Graft vs. host disease 1 GVHD) was not seen any patient.
The control recipients of a kidney only have been followed for 4.9::0.5 months: all are alive and have functioning allografts (Table 11 . The mean serum creatinine and BUN are 2.4::: 1.0 mg/dl and 50::32 mgtdl. None of these patients has been weaned off prednisone as of yet-however. this is most likely related to the relatively short follow-up. '!\vo 1:25%) patients had acute tubular necrosis (ATN), although only 1 
(63'k)
2125'}) ( 13%) required dialysis during the first week after transplantation. The incidence of acute rejection was 63% (5 patients J. All rejections were responsive to steroids and an increase in FK506. CMV was seen in 2 (25%) patients; both patients were successfully treated with gancyclovir. GVHD was not seen.
In the kidneylbone marrow patients. evidence of chimerism was present by at least one of the three modalities in 9 of 9 (100%) evaluable patients (Table 21 . The tenth patient, who 
, All determInatlOns performed >90 days alter transplantatlOn.
" Fluorescent In-SItu hybridizatlOn for Y·chromosome was per· tiJrmed In female recipients of male organs. Also receIved islets. , NA: test not performed because of lack of feaSIbility I perfect DR match and lack of sex dispanty or availabihtv of antibody to mIsmatched HLA A. 13 antigens).
. Chimerism was also detected by compeutive PCR and was found to be O.5{"c. received a I-B, 2-DR matched same-sex allograft. was not evaluable for microchimerism by any of these technologies. FACS was positive in 5 of7 patients in whom evaluation was feasible. with a range of 0.9-3.0%. PCR for HLA disparities was positive in 8 of 8 patients in whom the study could be performed (Fig. ll. In the three female recipients of kidneys from male donors. Y-chromosome detection by PCR was positive in all cases and in one, competitive PCR ((j) demonstrated a concentration of 0.5% donor DNA in PBMCs at 1 year. Using FISH for V-chromosome detection, a level of 0.2-1.4% was seen (Fig. 2 ). In the kidney alone patients, 3 of the B patients could not be evaluated for microchimerism by any modality, because of complete DR matching and lack of donor sex disparity. In the [) evaluable patients. :3 (60'7<,) were pOSitive for microchimerism by peR. 1 by HLA disparIty, and 2 by V-chromosome analysis. However. FACS failed to detect microchimerism in any of 3 evaluable patients by :3 months after transplantation.
Donor-specific reactivity could not be accurately assessed in 3 of the ten kidney/bone marrow recipients because there 1 3 7 14 300 c-c+ was complete DR-matching and a decreased in vitro immunologic response both pre-and post-transplantation. In the other 7 patients studied over time, there was one example of donor-specific nonresponsiveness and 2 of decreased donorspecific responsiveness that waxed and waned (Fig. 3) , The other 4 patients retained donor-specific responsiveness. Only 5 of the 8 kidney-alone recipients were evaluable. One of the 5 has some evidence of decreasing responsiveness. These results and those with 7 subsequently treated kidney-bone marrow recipients have shown that kidneylbone marrow transplantation is straightforward to perform and is safe. There were no examples of GVHD. Stable chimerism estimated to be WOO-fold more dense than that occurring spontaneously (3) was regularly achieved. It should be emphasized that (as was expected) bone marrow infusion did not influence the early events after transplantation. The inci- dence of acute rejection, the rates of early nonfunction. and the number cytomegalovirus infections were similar to those seen in patients receiving kidneys alone. However, treatment of these early problems was straightforward. After passing through this phase of convalescence. which was equally volatile with or without bone marrow augmentation. the more densely chimeric cohort of kidney-marrow recipients appeared to be an advantaged group. There was lOOCk patient and graft survival. and early completion of steroid weaning in half the cases. The full benefit of the chimeric state is expected to take one or 2 years. or longer. This trial was begun with patients undergoing primary transplantation who had low PRAs. We are now broadening our indications for kidney/ bone marrow transplantation to include candidates undergoing retransplantation and/or those with high PRAs in order to assess the utility of adjuvant bone marrow in a more complex transplant setting. Historically important clinical attempts to facilitate kidney graft acceptance have been reported using adjunctive preoperative donor blood transfusions (7) or delayed (by 3 weeks) cryopreserved cadaveric donor bone marrow (8, 9). Unlike the premises of these earlier trials. our hypothesis was that long-term engraftment of the infused donor cells could occur without "making space" by host preconditioning, without an undue risk of GVHD, and using the same immunosuppressive strategy that fostered the previously unrecognized spontaneous development of microchimerism (1-3). The observations in the kidney recipients herein reported, as well as in recipients of livers and hearts (3) are confirmatory of these predictions.
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